| 1 |
33767436 | Generation of TRAIL-resistant cell line models reveals distinct adaptive mechanisms for acquired resistance and re-sensitization. | 2021 May |
1 |
| 2 |
34451917 | The Synergistic Activity of Bortezomib and TIC10 against A2058 Melanoma Cells. | 2021 Aug 20 |
2 |
| 3 |
32365976 | Chemotherapeutic Agents Sensitize Resistant Cancer Cells to the DR5-Specific Variant DR5-B more Efficiently than to TRAIL by Modulating the Surface Expression of Death and Decoy Receptors. | 2020 Apr 30 |
1 |
| 4 |
29661248 | The regulation of combined treatment-induced cell death with recombinant TRAIL and bortezomib through TRAIL signaling in TRAIL-resistant cells. | 2018 Apr 16 |
1 |
| 5 |
28553285 | Antitumor Activity of a Mesenchymal Stem Cell Line Stably Secreting a Tumor-Targeted TNF-Related Apoptosis-Inducing Ligand Fusion Protein. | 2017 |
1 |
| 6 |
28972304 | DR5-Cbl-b/c-Cbl-TRAF2 complex inhibits TRAIL-induced apoptosis by promoting TRAF2-mediated polyubiquitination of caspase-8 in gastric cancer cells. | 2017 Dec |
1 |
| 7 |
24909167 | TRAIL-R2-specific antibodies and recombinant TRAIL can synergise to kill cancer cells. | 2015 Apr 16 |
1 |
| 8 |
26547077 | Mutations Enhancing Selectivity of Antitumor Cytokine TRAIL to DR5 Receptor Increase Its Cytotoxicity against Tumor Cells. | 2015 Aug |
1 |
| 9 |
25041999 | sTRAIL coupled to liposomes improves its pharmacokinetic profile and overcomes neuroblastoma tumour resistance in combination with Bortezomib. | 2014 Oct 28 |
1 |
| 10 |
25219883 | Melatonin as a proteasome inhibitor. Is there any clinical evidence? | 2014 Oct 12 |
1 |
| 11 |
25289891 | Bortezomib sensitizes primary meningioma cells to TRAIL-induced apoptosis by enhancing formation of the death-inducing signaling complex. | 2014 Nov |
6 |
| 12 |
25310712 | Combination of TRAIL with bortezomib shifted apoptotic signaling from DR4 to DR5 death receptor by selective internalization and degradation of DR4. | 2014 |
1 |
| 13 |
25341043 | Bortezomib sensitises TRAIL-resistant HPV-positive head and neck cancer cells to TRAIL through a caspase-dependent, E6-independent mechanism. | 2014 Oct 23 |
6 |
| 14 |
25501831 | XIAP-targeting drugs re-sensitize PIK3CA-mutated colorectal cancer cells for death receptor-induced apoptosis. | 2014 Dec 11 |
1 |
| 15 |
23144078 | TRAIL conjugated to nanoparticles exhibits increased anti-tumor activities in glioma cells and glioma stem cells in vitro and in vivo. | 2013 Jan |
2 |
| 16 |
23179179 | TRAIL promotes membrane blebbing, detachment and migration of cells displaying a dysfunctional intrinsic pathway of apoptosis. | 2013 Mar |
1 |
| 17 |
24263099 | Bortezomib antagonizes microtubule-interfering drug-induced apoptosis by inhibiting G2/M transition and MCL-1 degradation. | 2013 Nov 21 |
1 |
| 18 |
22202031 | Proteasome inhibition overcomes TRAIL resistance in human hepatoblastoma cells. | 2012 Jan 1 |
1 |
| 19 |
22539118 | Cellular signal transduction can be induced by TRAIL conjugated to microcapsules. | 2012 Oct |
2 |
| 20 |
22902909 | Effects of bortezomib in sensitizing human prostate cancer cell lines to NK-mediated cytotoxicity. | 2012 Sep |
2 |
| 21 |
21220502 | Bortezomib sensitizes malignant human glioma cells to TRAIL, mediated by inhibition of the NF-{kappa}B signaling pathway. | 2011 Jan |
5 |
| 22 |
21393428 | Bortezomib sensitizes HCC cells to CS-1008, an antihuman death receptor 5 antibody, through the inhibition of CIP2A. | 2011 May |
2 |
| 23 |
21459798 | Bortezomib primes neuroblastoma cells for TRAIL-induced apoptosis by linking the death receptor to the mitochondrial pathway. | 2011 May 15 |
7 |
| 24 |
21525171 | Bortezomib primes glioblastoma, including glioblastoma stem cells, for TRAIL by increasing tBid stability and mitochondrial apoptosis. | 2011 Jun 15 |
5 |
| 25 |
21789791 | Novel insights into the synergistic interaction of Bortezomib and TRAIL: tBid provides the link. | 2011 May |
1 |
| 26 |
22120628 | p53-Independent up-regulation of a TRAIL receptor DR5 by proteasome inhibitors: a mechanism for proteasome inhibitor-enhanced TRAIL-induced apoptosis. | 2011 Dec 9 |
3 |
| 27 |
24212664 | The Proteasome Inhibitor Bortezomib Sensitizes AML with Myelomonocytic Differentiation to TRAIL Mediated Apoptosis. | 2011 Mar 15 |
1 |
| 28 |
19768634 | Bortezomib sensitizes primary human esthesioneuroblastoma cells to TRAIL-induced apoptosis. | 2010 Apr |
6 |
| 29 |
19922463 | Bortezomib restores stroma-mediated APO2L/TRAIL apoptosis resistance in multiple myeloma. | 2010 Mar |
6 |
| 30 |
20126991 | Primary ovarian cancer cells are sensitive to the proaptotic effects of proteasome inhibitors. | 2010 Mar |
1 |
| 31 |
20213120 | Optimized combination therapy using bortezomib, TRAIL and TLR agonists in established breast tumors. | 2010 Jul |
1 |
| 32 |
20393880 | Bortezomib synergizes TRAIL-induced apoptosis in gastric cancer cells. | 2010 Dec |
12 |
| 33 |
20442297 | Bortezomib sensitizes human renal cell carcinomas to TRAIL apoptosis through increased activation of caspase-8 in the death-inducing signaling complex. | 2010 May |
7 |
| 34 |
20461078 | Novel SMAC-mimetics synergistically stimulate melanoma cell death in combination with TRAIL and Bortezomib. | 2010 Jun 8 |
1 |
| 35 |
20471514 | Synergistic antiproliferative effect of arsenic trioxide combined with bortezomib in HL60 cell line and primary blasts from patients affected by myeloproliferative disorders. | 2010 Jun |
1 |
| 36 |
20515944 | Bortezomib sensitizes human esophageal squamous cell carcinoma cells to TRAIL-mediated apoptosis via activation of both extrinsic and intrinsic apoptosis pathways. | 2010 Jun |
6 |
| 37 |
20542572 | The proteasome inhibitor bortezomib disrupts tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) expression and natural killer (NK) cell killing of TRAIL receptor-positive multiple myeloma cells. | 2010 Aug |
9 |
| 38 |
20561413 | [Effect of bortezomib on sensitization of HL-60 cells to TRAIL]. | 2010 Jun |
5 |
| 39 |
18922853 | Primitive quiescent CD34+ cells in chronic myeloid leukemia are targeted by in vitro expanded natural killer cells, which are functionally enhanced by bortezomib. | 2009 Jan 22 |
1 |
| 40 |
19039521 | Bortezomib treatment of ovarian cancer cells mediates endoplasmic reticulum stress, cell cycle arrest, and apoptosis. | 2009 Dec |
2 |
| 41 |
19100720 | Cooperation between Apo2L/TRAIL and bortezomib in multiple myeloma apoptosis. | 2009 Mar 1 |
14 |
| 42 |
19261616 | Bortezomib overcomes tumor necrosis factor-related apoptosis-inducing ligand resistance in hepatocellular carcinoma cells in part through the inhibition of the phosphatidylinositol 3-kinase/Akt pathway. | 2009 Apr 24 |
9 |
| 43 |
18160669 | Bortezomib blocks Bax degradation in malignant B cells during treatment with TRAIL. | 2008 Mar 1 |
2 |
| 44 |
18223318 | Proteasome inhibitor Bortezomib induces cell cycle arrest and apoptosis in cell lines derived from Ewing's sarcoma family of tumors and synergizes with TRAIL. | 2008 Apr |
2 |
| 45 |
18483298 | Proteasome inhibitor PS-341 (VELCADE) induces stabilization of the TRAIL receptor DR5 mRNA through the 3'-untranslated region. | 2008 May |
10 |
| 46 |
18544564 | Hypoxia-inducible factor-2alpha regulates the expression of TRAIL receptor DR5 in renal cancer cells. | 2008 Sep |
2 |
| 47 |
18716397 | Antitumor activity of bortezomib alone and in combination with TRAIL in human acute myeloid leukemia. | 2008 |
2 |
| 48 |
17237443 | Selective inhibition of IkappaB kinase sensitizes mantle cell lymphoma B cells to TRAIL by decreasing cellular FLIP level. | 2007 Feb 1 |
1 |
| 49 |
17326159 | TRAIL/bortezomib cotreatment is potentially hepatotoxic but induces cancer-specific apoptosis within a therapeutic window. | 2007 Mar |
8 |
| 50 |
17327374 | Proteasome inhibitors synergize with tumor necrosis factor-related apoptosis-induced ligand to induce anaplastic thyroid carcinoma cell death. | 2007 May |
1 |